(西藏 002826.sz) | 47.45 | 5.08 | 0.46% (0.46%) | 上市时间2016-12-09股价21.37元涨跌幅6.69%成交金额2.01亿元换手率5.27%市值40.75亿元A股市值40.75亿元流通市值39.10亿元自由流通市值27.88亿元总股东人数1.61万人均自由流通市值17.34万元总股本1.91亿流通A股1.83亿上市至今年化投资收益率-2.69%质押股数与前十大股东持股之比31.32% (4.96亿元2026-04-10) 实际控制人类型高帆 (自然人) 2026 一季报 公告日期2026-04-282025 年报 公告日期2026-04-282025 年报 业绩预估大幅上升 | |||
| 所属三级行业中药 (申万) | 市盈率 | 30.59 | 市净率 | 2.28 | 股息率 | 2.98% (2.54%) | 申万:医药生物中药中药申万2021版:医药生物化学制药化学制剂国证:医药卫生制药化学制剂 |
| 所属指数指数纳入纳出 | |||||||
| 备注 (2): | 双击编辑备注 |
易明医药(002826) - subsidiary companies
最后更新于：2024-12-31
Currently, this data is produced by lixinger AI extractor platform and only includes data from the 2024 annual reports onwards. It is in the gradual testing and rollout phase. We have not yet intervened with manual data cleaning, and therefore cannot guarantee the completeness and accuracy of data for all listed companies. If you find any issues, please click the "Submit Feedback" button in the middle left corner.
| 公司名称 | company type | 主营业务 | 注册资本 | paid-in capital | 总资产 | net assets | operating revenue | operating profit | 净利润 | shareholding ratio |
|---|---|---|---|---|---|---|---|---|---|---|
| 维奥制药 | 子公司 | 药品生产；药品进出口；药品委托生产；药品零售；药品批发；中药提取物生产；医学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广 | 2,600万元 | -- | 3.76亿元 | 3.07亿元 | 1.07亿元 | 2,391.09万元 | 1,574.29万元 | -- |